Epigenetic regulation of microRNA expression in Hodgkin lymphoma

Leuk Lymphoma. 2015;56(9):2683-9. doi: 10.3109/10428194.2014.995650. Epub 2015 Jun 18.

Abstract

Epigenetic mechanisms are crucial for the inactivation of key genes related to the survival of Hodgkin lymphoma (HL) cells, and methylation is a frequent epigenetic mechanism of microRNA silencing. We have examined the methylation-induced silencing of tumor suppressor microRNAs in HL cell lines and confirmed our results in patient lymph nodes. In addition, we evaluated the in vitro effectiveness of 5-aza-2-deoxycytidine (5-Aza-dC) in HL cell lines. Ten microRNAs containing CpG islands in their promoter region were re-expressed in both the L-428 and L-1236 cell lines. Interestingly, miR-34a and miR-203, both known tumor suppressor microRNAs, were found to be methylated in cell lines and in patient samples. 5-Aza-dC treatment resulted in a dose-dependent antiproliferative effect at 72 h in all the HL cell lines. In summary, 5-Aza-dC treatment of HL cell lines inhibits proliferation at high doses and produces re-expression of the tumor suppressor microRNAs at low-intermediate doses.

Keywords: Lymphoma and Hodgkin disease; cell lines and animal models; chemotherapeutic approaches.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azacitidine / analogs & derivatives
  • Azacitidine / pharmacology
  • Cell Line, Tumor
  • Cluster Analysis
  • DNA Methylation
  • Decitabine
  • Epigenesis, Genetic*
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic* / drug effects
  • Gene Silencing
  • Hodgkin Disease / genetics*
  • Hodgkin Disease / pathology
  • Humans
  • Lymph Nodes / metabolism
  • Lymph Nodes / pathology
  • MicroRNAs / genetics*
  • Promoter Regions, Genetic
  • Reproducibility of Results
  • Transcriptome

Substances

  • MicroRNAs
  • Decitabine
  • Azacitidine